A phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety, and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation.

vabametkib (ABN401) - Abion

https://www.asco.org/abstracts-presentations/265992

Xiuning Le; Jong Ran Kim; Hye Ryun Kim; Dae Ho Lee; Se-Hoon Lee; Ki Hyeong Lee; Ji-Youn Han; Yu Jung Kim; Gyeong-won Lee; Young Saing Kim

Apr 21, 2026